If you’re keeping an eye on breakthrough sectors and standout stocks, Eli Lilly is a name you probably can’t ignore. Despite recent market turbulence, this pharmaceutical powerhouse continues to capture investor attention with its innovative drugs and strong growth prospects. Here’s why Eli Lilly remains a compelling story for traders—even as the stock rides through ups and downs in 2025.
Obesity is becoming an increasingly serious problem and is officially considered the number 1 cause of death. According to World Health Organisation estimates, in one decade the numbers have tripled. Now more than 1 billion people worldwide are obese – 650 million adults, 340 million adolescents and 39 million children. This number is still rising and by 2025, another approximately 167 million people – adults and children – will become less healthy because they are overweight or obese.